Outcome of the Board Meeting for the quarter ending 30 June, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 3.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syschem India's board approved unaudited Q1 FY26 results (quarter ended 30 June 2025). Revenue from operations grew to Rs. 12,675.83 lakh, up about 24% from Rs. 10,215.17 lakh in the same quarter last year. Profit before tax jumped sharply to Rs. 167.35 lakh versus Rs. 13.67 lakh in Q1 FY25, with PAT also at Rs. 167.35 lakh (no tax expense in the quarter). EPS for the quarter stood at Rs. 0.38 vs Rs. 0.03 earlier. The board also approved the appointment/reappointment of statutory auditor M/s STAV & Co, secretarial auditor Mr. Kanwaljit Singh, and cost auditor M/s Mohit Aggarwal & Co for terms up to 2031. Additionally, 10 lakh ESOP options were granted at Rs. 10 each (face value) to nine employees under ESOS-2024, vesting equally over four years. The 32nd AGM is fixed for 4 September 2025 via video conferencing, with book closure from 29 August to 4 September.
Strong quarter for shareholders with revenue rising over 24% YoY and profits surging more than 10x, indicating margin expansion and improved operating performance in the pharmaceutical API segment. The large ESOP grant at face value could lead to mild equity dilution if exercised, but signals management confidence and an attempt to retain key staff.